...
首页> 外文期刊>Physiological Research >Serum Nesfatin-1 Levels in Patients With Different Glucose Tolerance Levels
【24h】

Serum Nesfatin-1 Levels in Patients With Different Glucose Tolerance Levels

机译:不同糖耐量水平患者的血清Nesfatin-1水平

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

The aim of this study was to compare the levels of nesfatin-1 in healthy subjects with those in prediabetic and diabetic patients who have different glucose tolerance levels. Overall, 100 subjects were divided into 5 groups healthy control (C), impaired fasting glycemia (IFG), impaired glucose tolerance (IGT), metabolic syndrome (MS) and type 2 diabetes mellitus, (Type 2 DM). Glycated hemoglobin (HbA1c) assessed the glycemic control. Homeostasis model assessment of insulin resistance (HOMA-IR) was determined using computer analyses. Nesfatin-1 levels were measured using ELISA method. IFG and IGT (prediabetic groups) from MS and Type 2 DM (diabetic groups) differed significantly in HOMA-IR. The nesfatin-1 levels were lower, although not statistically significant, in IFG (0.937+/-0.03 ng/ml, p=0.07) and IGT (1.039+/-0.06 ng/ml, p=0.5) groups compared to healthy subjects (1.094+/-0.07 ng/ml). However, the nesfatin-1 levels were lower in patients with Type 2 DM (0.867+/-0.02 ng/ml, p=0.007) and MS (0.885+/-0.01 ng/ml, p=0.01) compared to healthy subjects. Nesfatin-1 levels were significantly lower in diabetic patients compared to healthy subjects. This study supports the role of insulin resistance in decreased nesfatin-1 levels in patients with Type 2 DM and MS.
机译:本研究的目的是比较健康受试者中nesfatin-1的水平与糖耐量水平不同的糖尿病前期和糖尿病患者中的nesfatin-1水平。总体而言,将100名受试者分为5组:健康对照组(C),空腹血糖受损(IFG),葡萄糖耐量受损(IGT),代谢综合征(MS)和2型糖尿病(2型DM)。糖化血红蛋白(HbA1c)评估了血糖控制。使用计算机分析确定胰岛素抵抗的稳态模型评估(HOMA-IR)。使用ELISA方法测量Nesfatin-1水平。 MS和2型DM(糖尿病组)的IFG和IGT(糖尿病前组)在HOMA-IR中有显着差异。与健康受试者相比,IFG(0.937 +/- 0.03 ng / ml,p = 0.07)和IGT(1.039 +/- 0.06 ng / ml,p = 0.5)组的nesfatin-1水平较低,尽管无统计学意义。 (1.094 +/- 0.07 ng / ml)。然而,与健康受试者相比,患有2型DM(0.867 +/- 0.02 ng / ml,p = 0.007)和MS(0.885 +/- 0.01 ng / ml,p = 0.01)的患者的nesfatin-1水平较低。与健康受试者相比,糖尿病患者的Nesfatin-1水平显着降低。这项研究支持胰岛素抵抗在2型DM和MS患者中降低nesfatin-1水平的作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号